SCHEMBL7569718

SCHEMBL7569718

COC(=O)c1ccc(CCl)nc1-c1ccc(F)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.52
RAB9A P51151 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
CASP3 P42574 1/20 0.52
SENP8 Q96LD8 1/20 0.52
SENP7 Q9BQF6 1/20 0.52
SENP6 Q9GZR1 1/20 0.52
SLC6A4 P31645 1/20 0.47
SLC6A3 Q01959 1/20 0.47
LMNA P02545 1/20 0.44
MAPT P10636 3/20 0.42
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41
ALDH1A1 P00352 3/20 0.40
GCGR P47871 2/20 0.40
PKM P14618 1/20 0.40
MAPK13 O15264 1/20 0.40
ALOX5 P09917 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2513073 0.82 NPC1 (0.56) NPC1RAB9ASMN1; SMN2CASP3SENP8
SCHEMBL7566122 0.80 NPC1 (0.61) NPC1RAB9ASMN1; SMN2CASP3SENP8
SCHEMBL7562908 0.80 NPC1 (0.57) NPC1RAB9ASMN1; SMN2CASP3SENP8
SCHEMBL5264429 0.77 SMN1; SMN2 (0.53) NPC1RAB9ASMN1; SMN2CASP3SENP8
SCHEMBL15028918 0.76 KDM4E (0.45) NPC1RAB9ASMN1; SMN2CASP3SENP8
SCHEMBL23958825 0.75 SMN1; SMN2 (0.51) NPC1RAB9ASMN1; SMN2CASP3SENP8
SCHEMBL23930037 0.74 SMN1; SMN2 (0.50) NPC1RAB9ASMN1; SMN2CASP3SENP8
SCHEMBL30006707 0.74 SMN1; SMN2 (0.50) NPC1RAB9ASMN1; SMN2CASP3SENP8
SCHEMBL23958828 0.73 SMN1; SMN2 (0.52) NPC1RAB9ASMN1; SMN2CASP3SENP8
SCHEMBL2579354 0.72 LMNA (0.49) NPC1RAB9ASMN1; SMN2CASP3SENP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020058665-A1 Imidazole derivatives and their use as farnesyl protein transferase inhibitors ASTRAZENECA UK LIMITED 2002-05-16 US disclosed
US-20020052376-A1 Imidazole derivatives and their use as farnesyl protein transferase inhibitors ASTRAZENECA UK LIMITED 2002-05-02 US disclosed
US-6342765-B1 COMPOUNDS THAT INHIBIT FARNESYLATION OF MUTANT RAS GENE PRODUCTS; TREATING DISEASES, ESPECIALLY CANCER, WHICH ARE MEDIATED THROUGH FARNESYLATION OF RAS ASTRAZENECA UK LIMITED (GB) 2002-01-29 US disclosed
EP-1025088-B1 IMIDAZOLE DERIVATIVES AND THEIR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS ASTRAZENECA AB (SE) 2001-09-05 EP disclosed
EP-1025088-A1 IMIDAZOLE DERIVATIVES AND THEIR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS AstraZeneca UK Limited (GB) 2000-08-09 EP disclosed
WO-1999020611-A1 IMIDAZOLE DERIVATIVES AND THEIR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS ZENECA LIMITED (GB) 1999-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020058665-A1 Imidazole derivatives and their use as farnesyl protein transferase inhibitors FNTA, FNTB, RABGGTA NPC1 74/4885RAB9A 340/4885SMN1; SMN2 4776/4885
US-20020052376-A1 Imidazole derivatives and their use as farnesyl protein transferase inhibitors FNTA, FNTB, RABGGTA NPC1 102/4885RAB9A 254/4885SMN1; SMN2 4818/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.